Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niaosuanning (Jianpi Yishen Huazhuo) granules is a Traditional Chinese Medicine (TCM) formulation developed by The First Affiliated Hospital of Guangzhou University of Traditional Chinese Medicine. It is specifically indicated for the treatment of hyperuricemia. The formulation is based on the therapeutic principle of 'Jianpi Yishen Huazhuo,' which translates to strengthening the spleen, tonifying the kidney, and transforming metabolic turbidity. Administered orally as granules, the drug is being evaluated in clinical trials to compare its efficacy and safety against traditional decoctions and conventional western uric acid-lowering medications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Niaosuanning (Jianpi Yishen Huazhuo) granules.